全文获取类型
收费全文 | 1231篇 |
免费 | 82篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 32篇 |
妇产科学 | 27篇 |
基础医学 | 163篇 |
口腔科学 | 14篇 |
临床医学 | 102篇 |
内科学 | 364篇 |
皮肤病学 | 5篇 |
神经病学 | 280篇 |
特种医学 | 29篇 |
外科学 | 132篇 |
综合类 | 5篇 |
一般理论 | 1篇 |
预防医学 | 33篇 |
眼科学 | 8篇 |
药学 | 72篇 |
中国医学 | 5篇 |
肿瘤学 | 60篇 |
出版年
2023年 | 6篇 |
2022年 | 25篇 |
2021年 | 25篇 |
2020年 | 17篇 |
2019年 | 34篇 |
2018年 | 39篇 |
2017年 | 22篇 |
2016年 | 46篇 |
2015年 | 36篇 |
2014年 | 46篇 |
2013年 | 59篇 |
2012年 | 121篇 |
2011年 | 100篇 |
2010年 | 63篇 |
2009年 | 57篇 |
2008年 | 88篇 |
2007年 | 78篇 |
2006年 | 72篇 |
2005年 | 88篇 |
2004年 | 65篇 |
2003年 | 49篇 |
2002年 | 54篇 |
2001年 | 8篇 |
2000年 | 8篇 |
1999年 | 10篇 |
1998年 | 17篇 |
1997年 | 10篇 |
1996年 | 4篇 |
1995年 | 4篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 4篇 |
1991年 | 8篇 |
1989年 | 2篇 |
1988年 | 4篇 |
1987年 | 6篇 |
1986年 | 9篇 |
1985年 | 7篇 |
1984年 | 5篇 |
1979年 | 6篇 |
1978年 | 2篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1972年 | 1篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1969年 | 3篇 |
1968年 | 5篇 |
1967年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有1333条查询结果,搜索用时 15 毫秒
31.
32.
33.
34.
Eszter Banki Krisztina Kovacs Daniel Nagy Tamas Juhasz Peter Degrell Katalin Csanaky Peter Kiss Gabor Jancso Gabor Toth Andrea Tamas Dora Reglodi 《Journal of molecular neuroscience : MN》2014,54(3):300-309
Diabetic nephropathy is the leading cause of end-stage renal failure and accounts for 30–40 % of patients entering renal transplant programmes. The nephroprotective effects of the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP38) against diabetes have been shown previously, but the molecular mechanisms responsible for these effects remain unknown. In the present study, we showed that PACAP treatment counteracted the diabetes-induced increase in the level of the proapoptotic pp38MAPK and cleaved caspase-3 and also decreased the p60 subunit of NFκB. The examined antiapoptotic factors, including pAkt and pERK1/2, showed a slight increase in the diabetic kidneys, while PACAP treatment resulted in a notable elevation of these proteins. PCR and Western blot revealed the downregulation of fibrotic markers, like collagen IV and TGF-β1 in the kidney. PACAP treatment resulted in increased expression of the antioxidant glutathione. We conclude that the nephroprotective effect of PACAP in diabetes is, at least partly, due to its antiapoptotic, antifibrotic and antioxidative effect in addition to the previously described antiinflammatory effect. 相似文献
35.
Scott Nugent Sebastien Tremblay Kewei W. Chen Napatkamon Ayutyanont Auttawut Roontiva Christian-Alexandre Castellano Melanie Fortier Maggie Roy Alexandre Courchesne-Loyer Christian Bocti Martin Lepage Eric Turcotte Tamas Fulop Eric M. Reiman Stephen C. Cunnane 《Neurobiology of aging》2014
The extent to which the age-related decline in regional brain glucose uptake also applies to other important brain fuels is presently unknown. Ketones are the brain's major alternative fuel to glucose, so we developed a dual tracer positron emission tomography protocol to quantify and compare regional cerebral metabolic rates for glucose and the ketone, acetoacetate. Twenty healthy young adults (mean age, 26 years) and 24 healthy older adults (mean age, 74 years) were studied. In comparison with younger adults, older adults had 8 ± 6% (mean ± SD) lower cerebral metabolic rates for glucose in gray matter as a whole (p = 0.035), specifically in several frontal, temporal, and subcortical regions, as well as in the cingulate and insula (p ≤ 0.01, false discovery rate correction). The effect of age on cerebral metabolic rates for acetoacetate in gray matter did not reach significance (p = 0.11). Rate constants (min−1) of glucose (Kg) and acetoacetate (Ka) were significantly lower (−11 ± 6%; [p = 0.005], and −19 ± 5%; [p = 0.006], respectively) in older adults compared with younger adults. There were differential effects of age on Kg and Ka as seen by significant interaction effects in the caudate (p = 0.030) and post-central gyrus (p = 0.023). The acetoacetate index, which expresses the scaled residuals of the voxel-wise linear regression of glucose on ketone uptake, identifies regions taking up higher or lower amounts of acetoacetate relative to glucose. The acetoacetate index was higher in the caudate of young adults when compared with older adults (p ≤ 0.05 false discovery rate correction). This study provides new information about glucose and ketone metabolism in the human brain and a comparison of the extent to which their regional use changes during normal aging. 相似文献
36.
37.
Srdan Verstovsek Alessandro M. Vannucchi Martin Griesshammer Tamas Masszi Simon Durrant Francesco Passamonti Claire N. Harrison Fabrizio Pane Pierre Zachee Keita Kirito Carlos Besses Masayuki Hino Beatriz Moiraghi Carole B. Miller Mario Cazzola Vittorio Rosti Igor Blau Ruben Mesa Mark M. Jones Huiling Zhen Jingjin Li Nathalie Francillard Dany Habr Jean-Jacques Kiladjian 《Haematologica》2016,101(7):821-829
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera. This preplanned analysis occurred when all patients completed the Week 80 visit or discontinued. Objectives included evaluating the durability of the primary response (Week 32 phlebotomy-independent hematocrit control plus ≥35% spleen volume reduction), its components, and that of complete hematologic remission; and long-term safety. Median exposure was 111 weeks; 91/110 (82.7%) patients randomized to ruxolitinib remained on treatment. No patients continued best available therapy (98/112 [87.5%] crossed over to ruxolitinib, most at/soon after Week 32). At Week 32, primary response was achieved by 22.7% vs. 0.9% of patients randomized to ruxolitinib and best available therapy, respectively (hematocrit control, 60.0% vs. 18.8%; spleen response, 40.0% vs. 0.9%). The probability of maintaining primary and hematocrit responses for ≥80 weeks was 92% and 89%, respectively; 43/44 spleen responses were maintained until Week 80. Complete hematologic remission at Week 32 was achieved in 23.6% of ruxolitinib-randomized patients; the probability of maintaining complete hematologic remission for ≥80 weeks was 69%. Among ruxolitinib crossover patients, 79.2% were not phlebotomized, and 18.8% achieved a ≥35% reduction from baseline in spleen volume after 32 weeks of treatment. New or worsening hematologic laboratory abnormalities in ruxolitinib-treated patients were primarily grade 1/2 decreases in hemoglobin, lymphocytes, and platelets. The thromboembolic event rate per 100 patient-years was 1.8 with randomized ruxolitinib treatment vs. 8.2 with best available therapy. These data support ruxolitinib as an effective long-term treatment option for hydroxyurea-resistant or intolerant patients with polycythemia vera. This trial was registered at clinicaltrials.gov identifier: 01243944. 相似文献
38.
Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia 下载免费PDF全文
Rosemary Sutton Peter J. Shaw Nicola C. Venn Tamara Law Anuruddhika Dissanayake Tatjana Kilo Michelle Haber Murray D. Norris Chris Fraser Frank Alvaro Tamas Revesz Toby N. Trahair Luciano Dalla‐Pozza Glenn M. Marshall Tracey A. O'Brien 《British journal of haematology》2015,168(3):395-404
Minimal residual disease (MRD) during early chemotherapy is a powerful predictor of relapse in acute lymphoblastic leukaemia (ALL) and is used in children to determine eligibility for allogeneic haematopoietic stem cell transplantation (HSCT) in first (CR1) or later complete remission (CR2/CR3). Variables affecting HSCT outcome were analysed in 81 children from the ANZCHOG ALL8 trial. The major cause of treatment failure was relapse, with a cumulative incidence of relapse at 5 years (CIR) of 32% and treatment‐related mortality of 8%. Leukaemia‐free survival (LFS) and overall survival (OS) were similar for HSCT in CR1 (LFS 62%, OS 83%, n = 41) or CR2/CR3 (LFS 60%, OS 72%, n = 40). Patients achieving bone marrow MRD negativity pre‐HSCT had better outcomes (LFS 83%, OS 92%) than those with persistent MRD pre‐HSCT (LFS 41%, OS 64%, P < 0·0001) or post‐HSCT (LFS 35%, OS 55%, P < 0·0001). Patients with B‐other ALL had more relapses (CIR 50%, LFS 41%) than T‐ALL and the main precursor‐B subtypes including BCR‐ABL1, KMT2A (MLL), ETV6‐RUNX1 (TEL‐AML1) and hyperdiploidy >50. A Cox multivariate regression model for LFS retained both B‐other ALL subtype (hazard ratio 4·1, P = 0·0062) and MRD persistence post‐HSCT (hazard ratio 3·9, P = 0·0070) as independent adverse prognostic variables. Persistent MRD could be used to direct post‐HSCT therapy. 相似文献
39.
40.
Combined human papillomavirus typing and TP53 mutation analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma 下载免费PDF全文
Tamas Daher MD Mehmet Kemal Tur DMS Alexander Brobeil MD Benjamin Etschmann DVM Biruta Witte MD Rita Engenhart‐Cabillic MD Gabriele Krombach MD Wolfgang Blau MD Friedrich Grimminger MD Werner Seeger MD Jens Peter Klussmann MD Andreas Bräuninger PhD Stefan Gattenlöhner MD 《Head & neck》2018,40(6):1109-1119